ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer (CRATER)

Grants and Contracts Details

StatusFinished
Effective start/end date12/24/215/27/22

Funding

  • BeiGene Switzerland GmbH: $40,054.00